Novavax Statistics
Share Statistics
Novavax has 160.19M shares outstanding. The number of shares has increased by 14.46% in one year.
| Shares Outstanding | 160.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 152.99M |
| Failed to Deliver (FTD) Shares | 670 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 39.16M, so 24.45% of the outstanding shares have been sold short.
| Short Interest | 39.16M |
| Short % of Shares Out | 24.45% |
| Short % of Float | 25.59% |
| Short Ratio (days to cover) | 8.74 |
Valuation Ratios
The PE ratio is -0.89 and the forward PE ratio is -52.88.
| PE Ratio | -0.89 |
| Forward PE | -52.88 |
| PS Ratio | 0.87 |
| Forward PS | 2.9 |
| PB Ratio | -0.67 |
| P/FCF Ratio | -0.63 |
| PEG Ratio | n/a |
Enterprise Valuation
Novavax Inc. has an Enterprise Value (EV) of 185.39M.
| EV / Earnings | -0.34 |
| EV / Sales | 0.33 |
| EV / EBITDA | -0.38 |
| EV / EBIT | -0.33 |
| EV / FCF | -0.24 |
Financial Position
The company has a current ratio of 0.7, with a Debt / Equity ratio of -0.23.
| Current Ratio | 0.7 |
| Quick Ratio | 0.67 |
| Debt / Equity | -0.23 |
| Total Debt / Capitalization | -30.61 |
| Cash Flow / Debt | -4.25 |
| Interest Coverage | -39.3 |
Financial Efficiency
Return on equity (ROE) is 0.76% and return on capital (ROIC) is 116.56%.
| Return on Equity (ROE) | 0.76% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | 116.56% |
| Revenue Per Employee | 360.58K |
| Profits Per Employee | -353.25K |
| Employee Count | 1.54K |
| Asset Turnover | 0.31 |
| Inventory Turnover | 8.24 |
Taxes
| Income Tax | 2.03M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 76.8% in the last 52 weeks. The beta is 2.09, so Novavax 's price volatility has been higher than the market average.
| Beta | 2.09 |
| 52-Week Price Change | 76.8% |
| 50-Day Moving Average | 8.78 |
| 200-Day Moving Average | 10.64 |
| Relative Strength Index (RSI) | 52.81 |
| Average Volume (20 Days) | 5.11M |
Income Statement
In the last 12 months, Novavax had revenue of 556.38M and earned -545.06M in profits. Earnings per share was -5.41.
| Revenue | 556.38M |
| Gross Profit | 212.61M |
| Operating Income | -566.51M |
| Net Income | -545.06M |
| EBITDA | -487.39M |
| EBIT | -566.51M |
| Earnings Per Share (EPS) | -5.41 |
Balance Sheet
The company has 568.50M in cash and 229.08M in debt, giving a net cash position of 339.42M.
| Cash & Cash Equivalents | 568.50M |
| Total Debt | 229.08M |
| Net Cash | 339.42M |
| Retained Earnings | -4.82B |
| Total Assets | 1.71B |
| Working Capital | -77.32M |
Cash Flow
In the last 12 months, operating cash flow was -713.97M and capital expenditures -58.81M, giving a free cash flow of -772.77M.
| Operating Cash Flow | -713.97M |
| Capital Expenditures | -58.81M |
| Free Cash Flow | -772.77M |
| FCF Per Share | -7.67 |
Margins
Gross margin is 3.82K%, with operating and profit margins of -10.18K% and -9.80K%.
| Gross Margin | 3.82K% |
| Operating Margin | -10.18K% |
| Pretax Margin | -9.76K% |
| Profit Margin | -9.80K% |
| EBITDA Margin | -87.6% |
| EBIT Margin | -101.82% |
| FCF Margin | -138.89% |
Dividends & Yields
NVAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -61.2% |
| FCF Yield | -54.57% |
Analyst Forecast
The average price target for NVAX is $18.5, which is 109.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.5 |
| Price Target Difference | 109.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on May 10, 2019. It was a backward split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -3.71 |
| Piotroski F-Score | 4 |